Lyell Immunopharma Inc (LYEL)

$13.60 +0.73 (5.67%)
Market Cap 315.37M
Revenue (ttm) 40,000.00
Net Income (ttm) -274.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -686,125.05%
Debt to Equity Ratio 0.00
Volume 186,700
Avg Vol 187,056
Day's Range N/A - N/A
Shares Out 24.50M
Stochastic %K 83%
Beta -0.04
Analysts Strong Sell
Price Target $37.17

Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which i...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 695 0677
Address:
201 Haskins Way, Suite 101, South San Francisco, United States
Yashinvest
Yashinvest Jul. 31 at 7:00 AM
$LYEL Weekly chart, potential to double
0 · Reply
fantastex
fantastex Jul. 22 at 9:08 PM
$AMC this reminds me $LYEL and $NKTR charts. So....
0 · Reply
terra987
terra987 Jul. 22 at 1:57 PM
$LYEL As long as the new stockholder "Cellular Therapeutics" is selling (I guess almost everyday) we probably will not move upwards ....😩
2 · Reply
Quantumup
Quantumup Jul. 22 at 12:55 PM
BRiley🏁 $LYEL Buy-$44 and said -- LYEL is a registrational-stage oncology company with two cell therapy candidates for blood cancer and solid tumors. $GILD ACLX LEGN $IOVA NVS JNJ ALLO AUTL Here's what else BRiley had to say in its initiation report: https://x.com/Quantumup1/status/2079912722498457846?s=20
0 · Reply
fantastex
fantastex Jul. 20 at 7:47 PM
$AMC I saw this chart back when $LYEL or $AMLX went parabolic.
0 · Reply
fantastex
fantastex Jul. 17 at 2:26 PM
$ENGN so many sleepers on this $INO $LYEL $MRNA
0 · Reply
terra987
terra987 Jul. 9 at 10:05 AM
$LYEL $ABCL From ABCL board (I own both). lyel is on its way!! we will see hopefully 20 soon - abcl just recently went up strong and is under pressure now, profit taking.... ---------- $ABCL just added Dr. Lynn Seely to the board, a legit biotech operator with deep experience. Feels like a move to tighten execution as more antibody programs push into clinical development. Leadership quality matters more when the pipeline starts getting real.
0 · Reply
Mdugs
Mdugs Jul. 3 at 2:50 AM
$LYEL ceo Lynn the GOAT says the stock is undervalued. I believe her. Happy 4th
0 · Reply
Peterson28
Peterson28 Jun. 16 at 2:27 PM
$LYEL Likely to hover around $10-$12 for a while, as MM accumulates enough positions before we see another pump.
0 · Reply
focafoca99
focafoca99 Jun. 12 at 5:15 PM
$LYEL exhibited new safety and translational data for its ronde-cel CAR‑T therapy at the EHA 2026 Congress.
0 · Reply
Latest News on LYEL
Lyell Immunopharma initiated with a Buy at B. Riley

2026-07-22T09:05:14.000Z - 13 days ago

Lyell Immunopharma initiated with a Buy at B. Riley

Lyell Immunopharma files to sell 1.1M shares of common stock for holders

2026-07-13T21:20:07.000Z - 22 days ago

Lyell Immunopharma files to sell 1.1M shares of common stock for holders

Lyell Immunopharma Registration statement: Registration filing

Jul 13, 2026, 8:00 AM EDT - 22 days ago

Lyell Immunopharma Registration statement: Registration filing

AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 4 weeks ago

AbCellera apponts Lynn Seely to board of directors

ABCL

Lyell Immunopharma Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 30, 2026, 1:30 PM EDT - 5 weeks ago

Lyell Immunopharma Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 25, 2026, 8:00 AM EDT - 5 weeks ago

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

Jun 12, 2026, 12:45 PM EDT - 7 weeks ago

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

Lyell Immunopharma Transcript: AGM 2026

Jun 10, 2026, 11:00 AM EDT - 7 weeks ago

Lyell Immunopharma Transcript: AGM 2026

Lyell Immunopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 11:20 AM EDT - 2 months ago

Lyell Immunopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Lyell Immunopharma provides update on safety profile of LYL273

2026-06-08T10:05:20.000Z - 2 months ago

Lyell Immunopharma provides update on safety profile of LYL273

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Jun 8, 2026, 6:00 AM EDT - 2 months ago

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

Jun 4, 2026, 4:05 PM EDT - 2 months ago

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Lyell Immunopharma Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 20, 2026, 4:00 PM EDT - 2 months ago

Lyell Immunopharma Transcript: Stifel 2026 Targeted Oncology Virtual Forum

Lyell Immunopharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 11:00 AM EDT - 2 months ago

Lyell Immunopharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Lyell Immunopharma Announces Participation in May Investor Conferences

May 12, 2026, 8:00 AM EDT - 3 months ago

Lyell Immunopharma Announces Participation in May Investor Conferences

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

May 6, 2026, 4:05 PM EDT - 3 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

Lyell Immunopharma Quarterly report: Q1 2026

May 6, 2026, 4:00 PM EDT - 3 months ago

Lyell Immunopharma Quarterly report: Q1 2026

Lyell Immunopharma Earnings release: Q1 2026

May 6, 2026, 4:00 PM EDT - 3 months ago

Lyell Immunopharma Earnings release: Q1 2026

Lyell Immunopharma initiated with an Outperform at Baird on ronde-cel potential

2026-05-01T13:25:00.000Z - 3 months ago

Lyell Immunopharma initiated with an Outperform at Baird on ronde-cel potential

Lyell Immunopharma initiated with an Outperform at Baird

2026-04-30T20:51:07.000Z - 3 months ago

Lyell Immunopharma initiated with an Outperform at Baird

Lyell Immunopharma Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Lyell Immunopharma Proxy statement: Proxy filing

Lyell Immunopharma Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Lyell Immunopharma Proxy statement: Proxy filing

Lyell Immunopharma Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 11:00 AM EDT - 4 months ago

Lyell Immunopharma Transcript: 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst

2026-04-11T02:46:00.000Z - 4 months ago

Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst

Lyell Immunopharma initiated with a Buy at Needham

2026-04-10T10:06:03.000Z - 4 months ago

Lyell Immunopharma initiated with a Buy at Needham

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:00 AM EDT - 4 months ago

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma Registration statement: Registration filing

Apr 3, 2026, 8:00 AM EDT - 4 months ago

Lyell Immunopharma Registration statement: Registration filing

Lyell Immunopharma price target raised to $39 from $32 at Lucid Capital

2026-03-13T10:40:13.000Z - 5 months ago

Lyell Immunopharma price target raised to $39 from $32 at Lucid Capital

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Mar 12, 2026, 4:05 PM EDT - 5 months ago

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma Annual report: Q4 2025

Mar 12, 2026, 4:00 PM EDT - 5 months ago

Lyell Immunopharma Annual report: Q4 2025

Lyell Immunopharma Earnings release: Q4 2025

Mar 12, 2026, 4:00 PM EDT - 5 months ago

Lyell Immunopharma Earnings release: Q4 2025

Lyell Immunopharma Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 11:55 AM EDT - 5 months ago

Lyell Immunopharma Transcript: The Citizens Life Sciences Conference 2026

Lyell Immunopharma Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 10:00 AM EDT - 5 months ago

Lyell Immunopharma Transcript: Leerink Global Healthcare Conference 2026

Lyell Immunopharma appoints Smital Shah as CFBO

2026-03-09T12:15:08.000Z - 5 months ago

Lyell Immunopharma appoints Smital Shah as CFBO

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma initiated with an Outperform at Citizens

2026-03-09T08:50:14.000Z - 5 months ago

Lyell Immunopharma initiated with an Outperform at Citizens

Lyell Immunopharma Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 5 months ago

Lyell Immunopharma Transcript: TD Cowen 46th Annual Health Care Conference

Lyell Immunopharma Announces Participation in March Investor Conferences

Feb 23, 2026, 8:00 AM EST - 5 months ago

Lyell Immunopharma Announces Participation in March Investor Conferences

Lyell Immunopharma initiates patient dosing in PiNACLE-H2H Phase 3 trial

2026-02-12T12:35:32.000Z - 6 months ago

Lyell Immunopharma initiates patient dosing in PiNACLE-H2H Phase 3 trial

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

Feb 12, 2026, 7:30 AM EST - 6 months ago

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

Lyell Immunopharma Slides: Company presentation

Jan 23, 2026, 7:00 AM EST - 6 months ago

Lyell Immunopharma Slides: Company presentation

Lyell Immunopharma trading resumes

2025-12-22T17:15:21.000Z - 8 months ago

Lyell Immunopharma trading resumes

Lyell Immunopharma trading halted, volatility trading pause

2025-12-22T17:05:33.000Z - 8 months ago

Lyell Immunopharma trading halted, volatility trading pause

Lyell Immunopharma upgraded to Buy from Neutral at H.C. Wainwright

2025-12-09T11:15:12.000Z - 8 months ago

Lyell Immunopharma upgraded to Buy from Neutral at H.C. Wainwright

Lyell Immunopharma Transcript: Study Update

Dec 8, 2025, 8:30 AM EST - 8 months ago

Lyell Immunopharma Transcript: Study Update

Lyell Immunopharma Press release: Study Update

Dec 8, 2025, 8:30 AM EST - 8 months ago

Lyell Immunopharma Press release: Study Update

Lyell Immunopharma Slides: Study Update

Dec 8, 2025, 8:30 AM EST - 8 months ago

Lyell Immunopharma Slides: Study Update

Lyell Immunopharma announces new data from trial of rondecabtagene autoleucel

2025-12-08T01:40:05.000Z - 8 months ago

Lyell Immunopharma announces new data from trial of rondecabtagene autoleucel

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Dec 7, 2025, 4:30 PM EST - 8 months ago

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Lyell Immunopharma files to sell 1.9M shares of common stock for holders

2025-12-05T21:40:09.000Z - 8 months ago

Lyell Immunopharma files to sell 1.9M shares of common stock for holders

Lyell Immunopharma Registration statement: Registration Filing

Dec 5, 2025, 7:00 AM EST - 8 months ago

Lyell Immunopharma Registration statement: Registration Filing

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Nov 12, 2025, 4:05 PM EST - 9 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Lyell Immunopharma Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 9 months ago

Lyell Immunopharma Earnings release: Q3 2025

Lyell Immunopharma Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 9 months ago

Lyell Immunopharma Quarterly report: Q3 2025

Lyell Immunopharma Transcript: Investor Update

Nov 10, 2025, 8:30 AM EST - 9 months ago

Lyell Immunopharma Transcript: Investor Update

Lyell Immunopharma Press release: Investor Update

Nov 10, 2025, 8:30 AM EST - 9 months ago

Lyell Immunopharma Press release: Investor Update

Lyell Immunopharma Slides: Investor Update

Nov 10, 2025, 8:30 AM EST - 9 months ago

Lyell Immunopharma Slides: Investor Update

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

Nov 10, 2025, 7:30 AM EST - 9 months ago

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:00 AM EST - 9 months ago

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Lyell Immunopharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 10:00 AM EDT - 11 months ago

Lyell Immunopharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Lyell Immunopharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 9:15 AM EDT - 11 months ago

Lyell Immunopharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

Sep 3, 2025, 8:00 AM EDT - 11 months ago

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

Lyell Immunopharma Announces Participation in September Investor Conferences

Sep 2, 2025, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Announces Participation in September Investor Conferences

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Aug 12, 2025, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Lyell Immunopharma Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Quarterly report: Q2 2025

Lyell Immunopharma Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Earnings release: Q2 2025

Lyell Immunopharma Registration statement: Registration Filing

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Registration statement: Registration Filing

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Lyell Immunopharma Registration statement: Registration Filing

Jul 18, 2025, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Registration statement: Registration Filing

Lyell Immunopharma Transcript: H.C. Wainwright “HCW@Home” Series

Jun 25, 2025, 12:00 PM EDT - 1 year ago

Lyell Immunopharma Transcript: H.C. Wainwright “HCW@Home” Series

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 23, 2025, 5:00 PM EDT - 1 year ago

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Jun 17, 2025, 6:30 AM EDT - 1 year ago

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Lyell Immunopharma Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 10:00 AM EDT - 1 year ago

Lyell Immunopharma Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Jun 9, 2025, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Jun 4, 2025, 4:05 PM EDT - 1 year ago

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

May 13, 2025, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

Lyell Immunopharma Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Quarterly report: Q1 2025

Lyell Immunopharma Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Earnings release: Q1 2025

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

May 1, 2025, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

Lyell Immunopharma Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Proxy statement: Proxy Filing

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Apr 15, 2025, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Lyell Immunopharma Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Proxy statement: Proxy Filing

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Lyell Immunopharma Annual report: Q4 2024

Mar 11, 2025, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Annual report: Q4 2024

Lyell Immunopharma Earnings release: Q4 2024

Mar 11, 2025, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Earnings release: Q4 2024

Lyell Immunopharma Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:50 AM EST - 1 year ago

Lyell Immunopharma Transcript: TD Cowen 45th Annual Healthcare Conference

Lyell Immunopharma Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 25, 2025, 2:30 PM EST - 1 year ago

Lyell Immunopharma Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Feb 18, 2025, 4:05 PM EST - 1 year ago

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Lyell Immunopharma Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 12:00 PM EST - 1 year ago

Lyell Immunopharma Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Lyell Immunopharma Slides: FY 2025

Jan 15, 2025, 12:00 PM EST - 1 year ago

Lyell Immunopharma Slides: FY 2025

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Jan 9, 2025, 9:00 AM EST - 1 year ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Dec 9, 2024, 9:00 PM EST - 1 year ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Lyell Immunopharma Registration statement: Registration Filing

Nov 29, 2024, 7:00 AM EST - 1 year ago

Lyell Immunopharma Registration statement: Registration Filing

Lyell Immunopharma Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Lyell Immunopharma Earnings release: Q3 2024

Lyell Immunopharma Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Lyell Immunopharma Quarterly report: Q3 2024

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Nov 5, 2024, 9:30 AM EST - 1 year ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 31, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Lyell Immunopharma Transcript: M&A Announcement

Oct 24, 2024, 4:30 PM EDT - 1 year ago

Lyell Immunopharma Transcript: M&A Announcement

Lyell Immunopharma Press release: M&A Announcement

Oct 24, 2024, 4:30 PM EDT - 1 year ago

Lyell Immunopharma Press release: M&A Announcement

Lyell Immunopharma Slides: M&A Announcement

Oct 24, 2024, 4:30 PM EDT - 1 year ago

Lyell Immunopharma Slides: M&A Announcement

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Oct 24, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Sep 24, 2024, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Lyell Immunopharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 8:30 AM EDT - 2 years ago

Lyell Immunopharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Lyell Immunopharma Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 10:45 AM EDT - 2 years ago

Lyell Immunopharma Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Aug 7, 2024, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Lyell Immunopharma Quarterly report: Q2 2024

Aug 7, 2024, 4:00 PM EDT - 2 years ago

Lyell Immunopharma Quarterly report: Q2 2024

Lyell Immunopharma Earnings release: Q2 2024

Aug 7, 2024, 4:00 PM EDT - 2 years ago

Lyell Immunopharma Earnings release: Q2 2024

Lyell Immunopharma Transcript: Study Update

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Lyell Immunopharma Transcript: Study Update

Lyell Immunopharma Press release: Study Update

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Lyell Immunopharma Press release: Study Update

Lyell Immunopharma Slides: Study Update

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Lyell Immunopharma Slides: Study Update

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Jun 26, 2024, 7:00 AM EDT - 2 years ago

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Lyell Immunopharma Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 4:00 PM EDT - 2 years ago

Lyell Immunopharma Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Lyell Immunopharma Transcript: BofA Securities 2024 Health Care Conference

May 14, 2024, 11:40 AM EDT - 2 years ago

Lyell Immunopharma Transcript: BofA Securities 2024 Health Care Conference

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 7, 2024, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Lyell Immunopharma Quarterly report: Q1 2024

May 6, 2024, 7:30 AM EDT - 2 years ago

Lyell Immunopharma Quarterly report: Q1 2024

Lyell Immunopharma Earnings release: Q1 2024

May 6, 2024, 7:30 AM EDT - 2 years ago

Lyell Immunopharma Earnings release: Q1 2024

Lyell Immunopharma Slides: Q1 2024

May 6, 2024, 7:30 AM EDT - 2 years ago

Lyell Immunopharma Slides: Q1 2024

Lyell Immunopharma Proxy statement: Proxy Filing

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Lyell Immunopharma Proxy statement: Proxy Filing

Lyell Immunopharma Proxy statement: Proxy Filing

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Lyell Immunopharma Proxy statement: Proxy Filing

Lyell Immunopharma Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Mar 26, 2024, 3:30 PM EDT - 2 years ago

Lyell Immunopharma Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 2 years ago

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Lyell Immunopharma Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 4, 2024, 11:10 AM EST - 2 years ago

Lyell Immunopharma Transcript: TD Cowen 44th Annual Health Care Conference 2024

Lyell Immunopharma Registration statement: Registration Filing

Feb 29, 2024, 7:00 AM EST - 2 years ago

Lyell Immunopharma Registration statement: Registration Filing

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Feb 28, 2024, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Lyell Immunopharma Annual report: Q4 2023

Feb 28, 2024, 4:00 PM EST - 2 years ago

Lyell Immunopharma Annual report: Q4 2023

Lyell Immunopharma Earnings release: Q4 2023

Feb 28, 2024, 4:00 PM EST - 2 years ago

Lyell Immunopharma Earnings release: Q4 2023

Lyell Immunopharma Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 10, 2024, 11:15 AM EST - 2 years ago

Lyell Immunopharma Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Lyell Immunopharma Slides: FY 2024

Jan 10, 2024, 11:15 AM EST - 2 years ago

Lyell Immunopharma Slides: FY 2024

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Nov 9, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Lyell Immunopharma Quarterly report: Q3 2023

Nov 7, 2023, 4:00 PM EST - 2 years ago

Lyell Immunopharma Quarterly report: Q3 2023

Lyell Immunopharma Earnings release: Q3 2023

Nov 7, 2023, 4:00 PM EST - 2 years ago

Lyell Immunopharma Earnings release: Q3 2023

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 3 years ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lyell Immunopharma Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 11, 2023, 4:55 PM EDT - 3 years ago

Lyell Immunopharma Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Sep 11, 2023, 8:00 AM EDT - 3 years ago

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Aug 31, 2023, 4:05 PM EDT - 3 years ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Aug 8, 2023, 4:05 PM EDT - 3 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Lyell Immunopharma Quarterly report: Q2 2023

Aug 8, 2023, 4:00 PM EDT - 3 years ago

Lyell Immunopharma Quarterly report: Q2 2023

Lyell Immunopharma Earnings release: Q2 2023

Aug 8, 2023, 4:00 PM EDT - 3 years ago

Lyell Immunopharma Earnings release: Q2 2023

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Jul 5, 2023, 4:05 PM EDT - 3 years ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Yashinvest
Yashinvest Jul. 31 at 7:00 AM
$LYEL Weekly chart, potential to double
0 · Reply
fantastex
fantastex Jul. 22 at 9:08 PM
$AMC this reminds me $LYEL and $NKTR charts. So....
0 · Reply
terra987
terra987 Jul. 22 at 1:57 PM
$LYEL As long as the new stockholder "Cellular Therapeutics" is selling (I guess almost everyday) we probably will not move upwards ....😩
2 · Reply
Quantumup
Quantumup Jul. 22 at 12:55 PM
BRiley🏁 $LYEL Buy-$44 and said -- LYEL is a registrational-stage oncology company with two cell therapy candidates for blood cancer and solid tumors. $GILD ACLX LEGN $IOVA NVS JNJ ALLO AUTL Here's what else BRiley had to say in its initiation report: https://x.com/Quantumup1/status/2079912722498457846?s=20
0 · Reply
fantastex
fantastex Jul. 20 at 7:47 PM
$AMC I saw this chart back when $LYEL or $AMLX went parabolic.
0 · Reply
fantastex
fantastex Jul. 17 at 2:26 PM
$ENGN so many sleepers on this $INO $LYEL $MRNA
0 · Reply
terra987
terra987 Jul. 9 at 10:05 AM
$LYEL $ABCL From ABCL board (I own both). lyel is on its way!! we will see hopefully 20 soon - abcl just recently went up strong and is under pressure now, profit taking.... ---------- $ABCL just added Dr. Lynn Seely to the board, a legit biotech operator with deep experience. Feels like a move to tighten execution as more antibody programs push into clinical development. Leadership quality matters more when the pipeline starts getting real.
0 · Reply
Mdugs
Mdugs Jul. 3 at 2:50 AM
$LYEL ceo Lynn the GOAT says the stock is undervalued. I believe her. Happy 4th
0 · Reply
Peterson28
Peterson28 Jun. 16 at 2:27 PM
$LYEL Likely to hover around $10-$12 for a while, as MM accumulates enough positions before we see another pump.
0 · Reply
focafoca99
focafoca99 Jun. 12 at 5:15 PM
$LYEL exhibited new safety and translational data for its ronde-cel CAR‑T therapy at the EHA 2026 Congress.
0 · Reply
aletz
aletz Jun. 11 at 6:42 PM
$LYEL https://www.biostockinfo.com/biotech-catalyst-ai-scanner-june-wk3/ Picked as #5 pick this week from my AI Catalyst Scanner , Visit the link for more info. and catalyst driven investment ideas. Always do your own DD.
1 · Reply
terra987
terra987 Jun. 9 at 6:47 PM
$LYEL Sellers are gone?! Let's go to 100$ ... end of year.
0 · Reply
None_
None_ Jun. 9 at 12:35 AM
$LYEL https://www.globenewswire.com/news-release/2026/06/08/3307886/0/en/Lyell-Immunopharma-Provides-Update-on-Safety-Profile-of-LYL273-in-Relapsed-or-Refractory-Metastatic-Colorectal-Cancer-and-Amends-Phase-1-Trial-to-Phase-1-2-Expansion.html
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 8 at 12:21 PM
$LYEL (-17.2% pre) Lyell amends colorectal cancer trial after reducing side effects - SI https://ooc.bz/l/104414
0 · Reply
Mdugs
Mdugs Jun. 2 at 9:11 PM
$LYEL oooooof
2 · Reply
MarketBeat
MarketBeat May. 27 at 8:04 AM
https://marketbeat.com/a/8676251/ $LYEL Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances
0 · Reply
terra987
terra987 May. 21 at 10:38 AM
$LYEL Listened to the Stifel Forum talk: Lynn said (freely quoted!) "... J&J always wants to be the market leader; perhaps their technology has fallen behind, which is probably why they’ve discontinued their CD19/CD20 activities ... we’ve pursued a very aggressive strategy and it seems to be paying off ..." She came across as very convincing and I think everything is going according to plan so far. If the SP stays in the 17s some time or will even go lower I'll add even more.
0 · Reply
fantastex
fantastex May. 20 at 7:10 PM
$CRSR similar Pattern seen in $LYEL and $AMLX Pt $25
1 · Reply
Biocontrol
Biocontrol May. 19 at 3:32 PM
$LYEL J&J should buy this up to reboot their CAR 19/20 aspirations. Lynn is impressive.
1 · Reply
Mdugs
Mdugs May. 14 at 8:30 PM
$LYEL what’s up here
1 · Reply
Multiplyme7x
Multiplyme7x Apr. 25 at 12:28 PM
$XLO this is the same set up at $STRO stayed below $1 for many months then had a reverse split a few months after the split started going up now its above $30 check them out , $VOR and $LYEL also had reverse splits and headed north after a few months of nothing .
0 · Reply